抗肿瘤分子靶向药物安罗替尼的临床研究进展

Advances in clinical research of antitumor targeting drug anlotinib

综述新型小分子靶向抗肿瘤药物安罗替尼的Ⅱ,Ⅲ期临床研究进展,提出临床应用药物的展望。重点关注安罗替尼药物的作用机制、药动学及在疾病治疗中的应用。安罗替尼作为多靶点的酪氨酸激酶抑制剂,能够在抑制肿瘤血管新生的同时抑制肿瘤生长,临床效果显著,不良反应较少。对比其他替尼类靶向药物,使用安罗替尼药物的患者具有明显更长的中位无进展生存期,值得持续关注。

Review the Ⅱ ,Ⅲ period clinical research progress of the latest small molecules targeting antineoplastic drug Anlotinib,put forward the prospect of clinical application of drugs,focusing on the mechanism, pharmacokinetics of Anlotinib,and its applications in disease treatment.As a multi-target tyrosine kinase inhibitor, Anlotinib hydrochloride can inhibit angiogenesis while inhibiting tumor growth,the clinical effect is significant and the adverse reaction is less.Patients who use Anlotinib have a longer mPFS,compared with use other tini-targeted drugs.Anlotinib deserves further attention.